PCSK9 inhibitors for treating hypercholesterolemia.
作者： Andrea Pasta , Anna Laura Cremonini , Livia Pisciotta , Angelo Buscaglia , Italo Porto
DOI: 10.1080/14656566.2019.1702970
关键词: Pharmacodynamics 、 Statin 、 Bioinformatics 、 Medicine 、 PCSK9 、 PCSK9 Inhibitors 、 Dyslipidemia 、 Genetic model 、 Evolocumab 、 Health problems
摘要: Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering treatments has established that treatments aiming to lower low-density lipoprotein cholesterol (LDL-C) can reduce atherosclerosis. PCSK9 inhibitors (PCSK9-i), thanks to their efficacy in reducing LDL-C constitute a further step in the treatment of dyslipidemia and cardiovascular (CV) diseases. Areas covered: The purpose of this narrative review is to summarize the current knowledge of PCSK9-i, with particular regard to pharmacodynamic …
elsevier.com
sci-hub.se 参考文章(82)
Erik Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S. Rosenson, Gerald F. Watts, Eric Bruckert, Leslie Cho, Ricardo Dent, Beat Knusel, Allen Xue, Rob Scott, Scott M. Wasserman, Michael Rocco, Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance Journal of the American College of Cardiology. ,vol. 63, pp. 2541- 2548 ,(2014) , 10.1016/J.JACC.2014.03.019
James D Flaherty, Jeroen J Bax, Leonardo De Luca, Joseph S Rossi, Charles J Davidson, Gerasimos Filippatos, Peter P Liu, Marvin A Konstam, Barry Greenberg, Mandeep R Mehra, Günter Breithardt, Peter S Pang, James B Young, Gregg C Fonarow, Robert O Bonow, Mihai Gheorghiade, Acute Heart Failure Syndromes International Working Group, None, Acute Heart Failure Syndromes in Patients With Coronary Artery Disease : Early Assessment and Treatment Journal of the American College of Cardiology. ,vol. 53, pp. 254- 263 ,(2009) , 10.1016/J.JACC.2008.08.072
Michael J. Koren, Pernille Lundqvist, Michael Bolognese, Joel M. Neutel, Maria Laura Monsalvo, Jingyuan Yang, Jae B. Kim, Rob Scott, Scott M. Wasserman, Harold Bays, Anti-PCSK9 Monotherapy for Hypercholesterolemia Journal of the American College of Cardiology. ,vol. 63, pp. 2531- 2540 ,(2014) , 10.1016/J.JACC.2014.03.018
Robert P. Giugliano, Marc S. Sabatine, Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? Journal of the American College of Cardiology. ,vol. 65, pp. 2638- 2651 ,(2015) , 10.1016/J.JACC.2015.05.001
Željko Reiner, Management of patients with familial hypercholesterolaemia Nature Reviews Cardiology. ,vol. 12, pp. 565- 575 ,(2015) , 10.1038/NRCARDIO.2015.92
Patrick M Moriarty, Paul D Thompson, Christopher P Cannon, John R Guyton, Jean Bergeron, Franklin J Zieve, Eric Bruckert, Terry A Jacobson, Stephen L Kopecky, Marie T Baccara-Dinet, Yunling Du, Robert Pordy, Daniel A Gipe, Odyssey Alternative Investigators, None, Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial Journal of Clinical Lipidology. ,vol. 9, pp. 758- 769 ,(2015) , 10.1016/J.JACL.2015.08.006
Hong-ping Zhao, Bing-ren Xiang, Discontinued cardiovascular drugs in 2013 and 2014 Expert Opinion on Investigational Drugs. ,vol. 24, pp. 1083- 1092 ,(2015) , 10.1517/13543784.2015.1051619
Željko Reiner, PCSK9 inhibitors - past, present and future. Expert Opinion on Drug Metabolism & Toxicology. ,vol. 11, pp. 1517- 1521 ,(2015) , 10.1517/17425255.2015.1075506
Arihiro Kiyosue, Narimon Honarpour, Christopher Kurtz, Allen Xue, Scott M. Wasserman, Atsushi Hirayama, A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. American Journal of Cardiology. ,vol. 117, pp. 40- 47 ,(2016) , 10.1016/J.AMJCARD.2015.10.021
Xin-Lin Zhang, Qing-Qing Zhu, Li Zhu, Jian-Zhou Chen, Qin-Hua Chen, Guan-Nan Li, Jun Xie, Li-Na Kang, Biao Xu, Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials BMC Medicine. ,vol. 13, pp. 123- 123 ,(2015) , 10.1186/S12916-015-0358-8